Yahoo Web Search

Search results

1. • Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to...

     Nature· 2 days ago

     In contrast to B-cell precursor acute lymphoblastic leukemia (ALL), molecular subgroups are less well defined in T-lineage ALL. Comprehensive ...

2. • 

     Toddler, 2, dies months after his snoring was mistaken for a 'chesty cough'

     The US Sun· 1 day ago

     The concerned mum took him to the GP four times in three months but when Mason started vomiting,...

3. • Small Business - Austin Daily Herald | Austin Daily Herald

     Austin Daily Herald· 3 days ago

     AML is a cancer of the blood and bone marrow and is the most common type of acute leukemia in adults. SENTI-202, a potential first-in-class Logic Gated ...

4. • EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for...

     WTNH-TV New Haven· 12 hours ago

     Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the ...

5. • Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update

     CBS 47 Fresno· 1 day ago

     As of May 9, 2024, Ryvu's cash position was $59.0M, inclusive of the first tranche of €8M in venture debt from the EIB, obtained in March. This cash position, and other secured funding sources ...

6. • Patients Over 80 Still Benefit From Treatment for AML Blood Cancer

     US News & World Report· 2 days ago

     Seniors over 80 with acute myeloid leukemia can safely and effectively take the standard targeted therapy for the blood cancer, a new study finds. The oral ...

7. • 

     Study: Older Adults With Aggressive Blood Cancer A | Newswise

     Newswise· 6 days ago

     Standard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over...

8. • IN8bio (NASDAQ:INAB) PT Lowered to $12.50 at HC Wainwright

     ETF DAILY NEWS· 6 hours ago

     IN8bio (NASDAQ:INAB – Free Report) had its price target decreased by HC Wainwright from $14.00 to $12.50 in a report released on Monday, Benzinga reports. HC Wainwright currently has a buy rating ...

9. • Bio-Path Holdings Inc (BPTH) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...

     GuruFocus.com via Yahoo Finance· 6 hours ago

     Positive Points Bio-Path Holdings Inc (NASDAQ:BPTH) reported positive interim results from Stage 2 of the Phase 2 clinical trial of prexigebersen for treating acute myeloid ...

10. • Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress - Innate Pharma (NASDAQ:IPHA)

      Benzinga· 1 day ago

      Two abstracts on SAR443579 (IPH6101), ANKET® platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under development by partner Sanofi in blood cancer Two abstracts on IPH6501, Innate's